Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
Avacta Impresses at ESMO with Positive Phase 1a Data for pre|CISION® Platform
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress
Avacta Unveils Data on First Dual-Payload Peptide Drug Conjugate at International Cancer Conference
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
Avacta’s pre|CISION® Platform Shortlisted for AIM Technology of the Year
Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.
Avacta Secures £3.25m Through Oversubscribed Placing and Amends Convertible Bond
Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50
Avacta Therapeutics (AIM: AVCT) Announces Agreement to Sell Coris Bioconcept SRL
Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL (“Coris”) to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million
Avacta (AIM: AVCT) Equity fundraise of £3.25 million
Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that it has raised gross proceeds of £3.25 million from long term, high net worth
Avacta Group PLC (AIM: AVCT) Q2 2025 Business Update
Outlining Progress Against Strategic Objectives
Avacta Group PLC (AIM:AVCT) Management Team Appointments
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Avacta Group PLC (AIM:AVCT) New Response in Phase 1b Trial
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
Avacta Group PLC (AIM:AVCT) Preliminary Full Year 2024 Results
Preliminary Results for the Year Ended December 31, 2024
Avacta Group PLC (AIM:AVCT) Avacta Change in Prelim Date Part 2
Update on timing of preliminary results announcement